Results 121 to 130 of about 11,074 (164)

Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer. [PDF]

Oncologist
Gheeya JS, Singh R, Li M, Ahmadian S, Shilo K, Sen T, Rolfo C, Carbone DP, Owen DH, Gandara DR.   +9 more
europepmc   +1 more source

Autopsy-Confirmed Giant Pleural Hematoma Due to Spontaneous Hemothorax in ALK-Rearranged and TP53-Mutant Lung Adenocarcinoma: A Case Report. [PDF]

Onco Targets Ther
Kishino K, Yomota M, Arai H, Hosomi Y.
europepmc   +1 more source

Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer. [PDF]

EClinicalMedicine
Hulskotte LMG, Veerman GDM, Lanser DAC, Reyners AKL, van Schaik RHN, Dingemans AC, Taxis K, Mathijssen RHJ, Jansman FGA.   +8 more
europepmc   +1 more source

Anaplastic Lymphoma Kinase Positive Aggressive Adult Lung Primary Inflammatory Myofibroblastoma Tumor: A Case and Literature Review. [PDF]

Pharmgenomics Pers Med
Xu P, Lu S.
europepmc   +1 more source

Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies. [PDF]

Nat Commun
Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Kumar P, Henry M, Marusyk V, Siqueira NSN, Gatenbee C, Ozakinci H, Bui M, Boyle TA, Scott J, Altrock PM, Pellini B, Haura E, Anderson ARA, Basanta D, Marusyk A.   +18 more
europepmc   +1 more source

Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer. [PDF]

Front Pharmacol
Shen H, Huang S, Zhang J.
europepmc   +1 more source

Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance. [PDF]

Front Oncol
Maiti S, Reji AR, Senthil S, R R, Solairaju R, Kunjumon R, Ghosh P, H P S, Sadhukhan P, Dutta A.   +9 more
europepmc   +1 more source

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer. [PDF]

Cancer Commun (Lond)
Lanser DAC, Heersche N, Muntinghe-Wagenaar MB, Ali MIM, Ulas EB, de Jonge E, Hoop EO, Paats MS, Bahce I, Croes S, Langen AJ, Hendriks LEL, Wekken AJ, Huitema ADR, Schaik RHN, Dingemans AC, Veerman GDM, Mathijssen RHJ.   +17 more
europepmc   +1 more source

Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II-III non-small cell lung cancer in Sri Lanka. [PDF]

BMJ Oncol
Joseph N, Kularatna S, Senanayake S.
europepmc   +1 more source

ALK-fusion-positive non-small cell lung cancer concomitant with 5q deletion myelodysplastic syndrome: a case report. [PDF]

Front Oncol
Hodroj MH, Moukadem H.
europepmc   +1 more source